TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38169667

Group type: EXPERIMENTAL
Intervention: Support from the pharmacy regarding self-care of the feet
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Self-management practices
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Assessment of risk using MyFoot Diabetes software
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Healthcare professional risk assessment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Suggestions for pharmacy support
Number of subjects: 17
Study: 38169749

Group type: EXPERIMENTAL
Intervention: Elacestrant (ELA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 0
Study: 38169790

Group type: EXPERIMENTAL
Intervention: SW-BIC-213 (25 μg)
Number of subjects: 2403

Group type: COMPARATOR
Intervention: BBIBP (homologous booster)
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: SW-BIC-213
Number of subjects: 2403

Group type: COMPARATOR
Intervention: BBIBP
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: SW-BIC-213 and BBIBP
Number of subjects: 2403
Study: 38169864

Group type: EXPERIMENTAL
Intervention: Family history of PD
Number of subjects: 395

Group type: COMPARATOR
Intervention: No family history of PD
Number of subjects: 395
Study: 38169917

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 28
Study: 38169944

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccination
Number of subjects: 34489

Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 34489
Study: 38169960

Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs) derived from adipose tissue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current EVs-based therapeutic strategies
Number of subjects: 0
Study: 38170033

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily with ASA 80 mg once daily
Number of subjects: 437

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily with ASA 80 mg once daily
Number of subjects: 437
Study: 38170085

Group type: EXPERIMENTAL
Intervention: Active rehabilitation alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Medial patellofemoral ligament reconstruction and active rehabilitation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Baseline single leg hop for distance
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Baseline triple hop for distance
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Knee injury and Osteoarthritis Outcome Score (KOOS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Limb Symmetry Index (LSI)
Number of subjects: 61
Study: 38170185

Group type: EXPERIMENTAL
Intervention: Ketamine treatment (dosage and duration not available)
Number of subjects: 0
Study: 38170227

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 38170246

Group type: EXPERIMENTAL
Intervention: Bioresorbable scaffolds (ABSORB BRS, Abbott Vascular)
Number of subjects: 35
Study: 38170248

Group type: EXPERIMENTAL
Intervention: HFpEF patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hospitalized patients during follow-up
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Impaired left atrial (LA) function at rest
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Impaired left atrial (LA) function during stress
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CMR-derived atrial function parameters at rest and during exercise-stress
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CMR-Feature Tracking LA Es/Ee
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: RT-CMR derived LA long axis strain
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Left atrial function
Number of subjects: 68
Study: 38170249

Group type: EXPERIMENTAL
Intervention: GLP-1 levels at ICU admission
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: GLP-1 levels above vs. below the median
Number of subjects: 172
Study: 38170256

Group type: EXPERIMENTAL
Intervention: Topical sodium valproate (SV) applied twice daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Topical mometasone furoate lotion applied twice daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Topical sodium valproate (SV) and topical steroids
Number of subjects: 66
Study: 38170263

Group type: EXPERIMENTAL
Intervention: Professional employment after VAD implantation
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) for employed patients
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Employment and history of adverse events
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Overall HRQoL perception
Number of subjects: 375
Study: 38170301

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Nausea (having vs. not having)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Pain (having vs. not having)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Patients' rating of the exercise intervention
Number of subjects: 122
Study: 38170393

Group type: EXPERIMENTAL
Intervention: DPI Easyhaler (PIFEH)
Number of subjects: 246
Study: 38170502

Group type: EXPERIMENTAL
Intervention: Linagliptin in CARMELINA trial
Number of subjects: 13012

Group type: EXPERIMENTAL
Intervention: Linagliptin in CAROLINA trial
Number of subjects: 13012
Study: 38170541

Group type: EXPERIMENTAL
Intervention: Home-use tDCS plus digital psychological intervention (double active)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Home-use tDCS plus digital placebo (tDCS only)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sham home-use tDCS plus digital placebo (double sham)
Number of subjects: 210
Study: 38170601

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.5 or 0.8 mEq/kg lean body weight per day) for 28 weeks
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 38170674

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38170741

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (INO) at a maximum tolerated dose (MTD) of 0.6 mg/m2, administered on day 1 of 28-day cycles.
Number of subjects: 18
Study: 38170953

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant (aHSCT)
Number of subjects: 1
Study: 38171034

Group type: EXPERIMENTAL
Intervention: 3 g/day of Ca-HMB with resistance training (3 sessions/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with resistance training (3 sessions/week)
Number of subjects: 0
Study: 38171156

Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 51
Study: 38171212

Group type: EXPERIMENTAL
Intervention: Text Message Intervention (TMI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced Usual Care (eUC)
Number of subjects: 60
Study: 38171619

Group type: EXPERIMENTAL
Intervention: STEMI patients (elderly and very socially disadvantaged)
Number of subjects: 9218

Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 9218
Study: 38171620

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass, gastric band, or sleeve gastrectomy)
Number of subjects: 758
Study: 38171623

Group type: EXPERIMENTAL
Intervention: Large-scale take-home naloxone distribution (2019-2021)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historic control period (2013-2017)
Number of subjects: 0
Study: 38171625

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 50
Study: 38171630

Group type: EXPERIMENTAL
Intervention: GOAL intervention (16-week program including after-school activities, parent meetings, and social networking)
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: GOAL intervention
Number of subjects: 882
Study: 38171633

Group type: EXPERIMENTAL
Intervention: Chronotherapy in addition to Treatment as Usual (TAU)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 76
Study: 38171926

Group type: EXPERIMENTAL
Intervention: Liver-directed gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy vectors and strategies for liver-targeting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene therapy administration in a fibrotic liver
Number of subjects: 0
Study: 38172296

Group type: EXPERIMENTAL
Intervention: ilofotase alfa
Number of subjects: 650

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 650
Study: 38172325

Group type: EXPERIMENTAL
Intervention: Remote measurements via videoconferencing
Number of subjects: 33

Group type: COMPARATOR
Intervention: In-person measurements with research staff
Number of subjects: 33
Study: 38172345

Group type: EXPERIMENTAL
Intervention: Caloric restriction
Number of subjects: 10
Study: 38172458

Group type: EXPERIMENTAL
Intervention: Alveolar ridge splitting (ARS) with guided bone regeneration (GBR) using simvastatin (SMV) gel mixed bone graft and a barrier membrane with simultaneous implant placement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Guided bone regeneration (GBR) without simvastatin (SMV) gel
Number of subjects: 22
Study: 38172659

Group type: EXPERIMENTAL
Intervention: Kiosk BP monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse-measured BP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician-measured BP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kiosk BP
Number of subjects: 0
Study: 38172712

Group type: EXPERIMENTAL
Intervention: Low-energy meal-replacement plan (MRP) (∼810 kcal/day) for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls (HC), N=25 (15 males, age 48.3±6.6 years)
Number of subjects: 24
Study: 38172750

Group type: EXPERIMENTAL
Intervention: Decreased cognition (MMSE score < 25)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Intact cognition (MMSE score ≥ 25)
Number of subjects: 119
Study: 38172780

Group type: EXPERIMENTAL
Intervention: ABLE 2.0 intervention
Number of subjects: 78
Study: 38172875

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 84
Study: 38172930

Group type: EXPERIMENTAL
Intervention: CDSS-OPTIMED intervention (software program providing weekly personalized medication recommendations)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 7
Study: 38172949

Group type: EXPERIMENTAL
Intervention: CEUS-CT/MRI fusion imaging (FI)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: CEUS addition to US-FI
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: CEUS-CT/MRI fusion imaging (FI) guided RFA
Number of subjects: 248
Study: 38172973

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA for 20 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 30
Study: 38172996

Group type: EXPERIMENTAL
Intervention: 250 μg/day B12 supplementation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 38173006

Group type: EXPERIMENTAL
Intervention: AAN-equipped TIGER
Number of subjects: 16

Group type: COMPARATOR
Intervention: Original TIGER
Number of subjects: 16
Study: 38173041

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patient activation
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Physical activity and non-motor symptoms interaction
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Physical activity and motor symptoms interaction
Number of subjects: 88
Study: 38173167

Group type: COMPARATOR
Intervention: i-CBT-only
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: i-CBT with stepped care
Number of subjects: 56
Study: 38173937

Group type: EXPERIMENTAL
Intervention: V-V ECMO
Number of subjects: 0
Study: 38174101

Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD)
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy (PSP)
Number of subjects: 1648

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1648
Study: 38174147

Group type: EXPERIMENTAL
Intervention: LCPT (Life cycle pharma tacrolimus) orally once daily at a starting dose of 0.13 mg/kg/day based on actual body weight.
Number of subjects: 0
Study: 38174154

Group type: EXPERIMENTAL
Intervention: Arteriogram
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Hypocalcemic stimulation
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Selective venous sampling (SVS)
Number of subjects: 94
Study: 38174564

Group type: EXPERIMENTAL
Intervention: Immediate antihypertensive treatment
Number of subjects: 4071

Group type: COMPARATOR
Intervention: Control (discontinue all antihypertensive agents)
Number of subjects: 4071
Study: 38174567

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT)
Number of subjects: 4841

Group type: COMPARATOR
Intervention: Aspirin and placebo
Number of subjects: 4841
Study: 38174568

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 1577

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 1577
Study: 38174577

Group type: EXPERIMENTAL
Intervention: erenumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: rimegepant
Number of subjects: 0
Study: 38174569

Group type: EXPERIMENTAL
Intervention: Asundexian 50 mg daily
Number of subjects: 1808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1808
Study: 38174611

Group type: EXPERIMENTAL
Intervention: MDMA-assisted psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance
Number of subjects: 0
Study: 38175228

Group type: EXPERIMENTAL
Intervention: Adjuvant transcranial direct current stimulation (tDCS) with intensive speech-language therapy for 3 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intensive speech-language therapy for 3 weeks
Number of subjects: 110
Study: 38175251

Group type: EXPERIMENTAL
Intervention: 700 mg phosphorus
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Phosphate with glucose
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Phosphate without glucose
Number of subjects: 28
Study: 38175339

Group type: EXPERIMENTAL
Intervention: Total synovitis uptake (TSU)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Metabolic synovitis volume (MSV)
Number of subjects: 19
Study: 38175364

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 764
Study: 38175391

Group type: EXPERIMENTAL
Intervention: Itanet database project
Number of subjects: 1600
Study: 38175448

Group type: EXPERIMENTAL
Intervention: neoadjuvant trastuzumab, pertuzumab, and docetaxel (DPH)
Number of subjects: 197

Group type: COMPARATOR
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: baseline sTK1 levels
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: sTK1 level after 2 and 4 cycles
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: sTK1 activity at end of treatment visit
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: sTK1 activity at baseline and cycle 2
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: event-free survival (EFS)
Number of subjects: 197
Study: 38175466

Group type: EXPERIMENTAL
Intervention: Cenegermin 20 mcg/ml, 1 drop in the affected eye(s) 6 times/day for 8 weeks
Number of subjects: 37
Study: 38175488

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray administered in < 5 min after seizure start
Number of subjects: 3225

Group type: EXPERIMENTAL
Intervention: Diazepam nasal spray administered in ≥ 5 min after seizure start
Number of subjects: 3225
Study: 38175595

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 101
Study: 38175627

Group type: EXPERIMENTAL
Intervention: Combination of fractionated stereotactic radiotherapy or whole-brain radiotherapy with pyrotinib (400 mg, once daily) and capecitabine (1000 mg/m2, twice daily, on days 1-14 of each 21-day cycle)
Number of subjects: 40
Study: 38175642

Group type: EXPERIMENTAL
Intervention: GLP-1RA
Number of subjects: 543595

Group type: COMPARATOR
Intervention: Basal insulin
Number of subjects: 543595
Study: 38175648

Group type: EXPERIMENTAL
Intervention: Mobile application (ICUconnect) intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mobile application (ICUconnect) intervention for White family members
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mobile application (ICUconnect) intervention for Black family members
Number of subjects: 111
Study: 38175669

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Endocrine Therapy (ET)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CDK4/6-inhibitors + Endocrine Therapy (ET)
Number of subjects: 49
Study: 38175837

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: School-based mass drug administration (MDA)
Number of subjects: 18
Study: 38175920

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38176013

Group type: EXPERIMENTAL
Intervention: Initiation of breastfeeding or provision of expressed breast milk
Number of subjects: 579

Group type: COMPARATOR
Intervention: HCV viremia (detectable viral load during pregnancy)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Undetectable viral load during pregnancy
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 579

Group type: COMPARATOR
Intervention: Public insurance or no insurance
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Duration of breastfeeding
Number of subjects: 579
Study: 38176019

Group type: EXPERIMENTAL
Intervention: Various biomarkers tested for early-stage ovarian cancer detection
Number of subjects: 131

Group type: COMPARATOR
Intervention: CA 125
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Biomarkers with better sensitivity
Number of subjects: 131
Study: 38176122

Group type: EXPERIMENTAL
Intervention: Self-determined sequence exercise program (SDSG, n = 34)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Strength training group (STG, n = 30)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (CG, n = 30)
Number of subjects: 94
Study: 38176228

Group type: EXPERIMENTAL
Intervention: Best medical therapy (BMT) involving antiplatelet agents, blood pressure control, and statins
Number of subjects: 307

Group type: COMPARATOR
Intervention: Stable plaque
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Plaque progression
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Contralateral carotid stenosis >60%
Number of subjects: 307
Study: 38176391

Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Individual Supportive Therapy (IST)
Number of subjects: 292
Study: 38176682

Group type: EXPERIMENTAL
Intervention: HemoCue 201+ analyzer using venous blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HemoCue 201+ analyzer using pooled capillary blood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HemoCue 201+ analyzer using single-drop capillary blood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference method using Sysmex XN-450 hematology analyzer with venous blood
Number of subjects: 0
Study: 38176698

Group type: EXPERIMENTAL
Intervention: Machine learning model using facial expressions
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Machine learning model combining facial expressions and vital signs
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Machine learning models using combined physiological signals (vital signs, ANI)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Absolute ANI
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Relative ANI
Number of subjects: 155
Study: 38176782

Group type: EXPERIMENTAL
Intervention: Mavacamten 5 mg once daily
Number of subjects: 231
Study: 38176840

Group type: EXPERIMENTAL
Intervention: MCPAP for Moms
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: PRISM
Number of subjects: 312
Study: 38176857

Group type: EXPERIMENTAL
Intervention: Amantadine for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Amantadine and TMS for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sham control) for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amantadine and/or TMS
Number of subjects: 0
Study: 38176863

Group type: EXPERIMENTAL
Intervention: AI-assisted CT-based lung cancer prediction tool (LCP)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2000
Study: 38176866

Group type: EXPERIMENTAL
Intervention: Oxygen-ozone therapy 2-3 times a week for 6 weeks (maximum of 15 sessions) with oral antibiotic therapy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Oral antibiotic therapy prescribed at baseline
Number of subjects: 186
Study: 38176872

Group type: EXPERIMENTAL
Intervention: On Your Own Feet Ahead theoretical framework
Number of subjects: 0
Study: 38176874

Group type: COMPARATOR
Intervention: Control+ONS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HMB+ONS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: VT+ONS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HMB+VT+ONS
Number of subjects: 200
Study: 38176875

Group type: EXPERIMENTAL
Intervention: Exercise Therapy (ET) - 12-week rehabilitation programme
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy (ESWT) - four sessions with 1 week rest between sessions during 1 month
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy (US-PICT) - two sessions with 3 months of rest between sessions
Number of subjects: 116

Group type: COMPARATOR
Intervention: Wait-and-see group - no intervention during the 12-month follow-up
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Psychosocial questionnaires
Number of subjects: 116